About 100 reports

  • RDX-023 - DRUG PROFILE
  • DIARRHEA - PIPELINE BY REDHILL BIOPHARMA LTD, H2 2017

It also offers uPA and inhibitors for the treatment of gastrointestinal, solid tumor cancers, pancreatic and other gastrointestinal cancers.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Synthetic Biologics

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Antimalarials
  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • AstraZeneca PLC
  • Research and Development Brief

The invention relates to methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer, it also relates to the treatment of inflammatory diseases.

  • Gastrointestinal Drug
  • Infectious Disease
  • World
  • Product Initiative
  • Salix Pharmaceuticals, Ltd.
  • Sucampo Pharmaceuticals Inc
  • Develco Pharma Schweiz AG

These medicines affect the gastrointestinal tract in a variety of ways.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • United States
  • Product Initiative
  • CJ-14199 - DRUG PROFILE

In April 2016, EA Pharma Co., Ltd. established by integration of the gastrointestinal business unit of the Eisai Group and the Ajinomoto Group s gastrointestinal business unit with the core in amino acid.

  • Gastrointestinal Drug
  • Japan
  • United States
  • Product Initiative
  • Albireo Limited
  • Jul 25, 2016: Biomerica Forms Strategic Advisory Board
  • Aug 30, 2016: Biomerica Announces Year End Results

He is an accomplished expert in afflictions of the gastrointestinal tract and IBS.

  • Gastrointestinal Drug
  • United States
  • Company Financials
  • Biomerica, Inc.
  • FEATURED NEWS & PRESS RELEASES
  • Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • United States
  • RedHill Biopharma Ltd.
  • RECCE LTD
  • FEATURED NEWS & PRESS RELEASES

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • United States
  • RedHill Biopharma Ltd.
  • Clinical Trial profile. 144 Trial Title
  • Clinical Trial profile. 91 Trial Title

Gastrointestinal Adverse Events Associated with a Colonoscopy Purgative The Effects of Nexium on the Side Effects Associated with a Colonoscopy Prep GDCT## NCT##, ##C. ## Central Nervous System Abdominal Pain, Emesis (Vomiting), Nausea Completed Phase IV Interventional esomepraz

  • Gastrointestinal Drug
  • Hospital
  • Neurology
  • World
  • Product Initiative
  • Clinical Trial profile. 25 Trial Title
  • Clinical Trial profile. 89 Trial Title

Gastrointestinal Spasm: A Post Marketing Observational Program in the Russian Federation Effectiveness of Duspatalin in Patients with Post-cholecystectomy Gastrointestinal Spasm (ODYSSEY) GDCT## NCT##, MEBE## Central Nervous System Abdominal Pain, Unspecified

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Neurology
  • World
  • Product Initiative
  • ZS-07 - DRUG PROFILE
  • NARONAPRIDE - DRUG PROFILE

It inhibits peripheral acetylcholinesterase activities in the gastrointestinal tract.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • Product Initiative
  • RaQualia Pharma Inc.
  • NARONAPRIDE - DRUG PROFILE
  • YH-12852 - DRUG PROFILE

It inhibits peripheral acetylcholinesterase activities in the gastrointestinal tract.

  • Gastrointestinal Drug
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.
  • 3.2 Key Trends & Developments
  • ARDELYX, Inc. Drugs Under Pipeline

These nerves control the functions of gastrointestinal tract.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Forecast
  • Sucampo Pharmaceuticals, Inc.
  • Five Key Clinical Profiles

PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2015* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2015* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%

  • Clinical Trial
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY REDHILL BIOPHARMA LTD, H1 2017
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY NEMUS BIOSCIENCE INC, H1 2017

The company' s pipeline products include oral combination therapy candidates for the treatment of helicobacter pylori infection, Crohn' s disease and multiple sclerosis; uPA inhibitor for the treatment of gastrointestinal and other solid tumor cancers; Hsp## inhibitor for the treatm

  • Chemotherapy
  • Gastrointestinal Drug
  • Therapy
  • United States
  • Product Initiative
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY NEMUS BIOSCIENCE INC
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY REDHILL BIOPHARMA LTD

The company' s franchise areas in research include neurology, oncology, vascular and immunological reaction, gastrointestinal disorders, and musculoskeletal diseases.

  • Blood Disease
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Pfizer Inc.

" Dacomitinib is a more potent, second-generation EGFR inhibitor that shares the issue of increased side effects in the skin and gastrointestinal tract, like afatinib (Gilotrif).

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial Profile Snapshots

Gastrointestinal Effects of Multiple-Dosed Intravenous Methylnaltrexone in Healthy Human Volunteers Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone GDCT## NCT##, MNTX ## Toxicology Opioid-Induced Constipation (OIC) Completed Phase II Interventional m

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • World
  • Product Initiative
  • TRAVELER'S DIARRHEA - PIPELINE BY SIGMOID PHARMA LIMITED, H2 2016
  • TRAVELER'S DIARRHEA - PIPELINE BY COSMO PHARMACEUTICALS NV, H2 2016

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Anti-Infective
  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Post Operative Nausea And Vomiting - Product Development Milestones

No prolongation of the QT interval was seen with APD## nor was there any evidence of sedation, psychological symptoms, extrapyramidal toxicity or gastrointestinal disturbance, a clear advantage over many other anti-emetics.

  • Gastrointestinal Drug
  • United States
  • World
  • Product Initiative
  • GW Pharmaceuticals plc
  • Product Description

For Gastrointestinal Therapies.

  • Gastrointestinal Drug
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.
  • TRAVELER'S DIARRHEA - PIPELINE BY COSMO PHARMACEUTICALS S.P.A, H1 2016
  • TRAVELER'S DIARRHEA - PIPELINE BY SIGMOID PHARMA LIMITED, H1 2016

The company develops, produces and markets optimized therapies for treatment of gastrointestinal diseases.

  • Anti-Infective
  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Beijing Minhai Biotechnology Co Ltd
  • Research and Development Brief

The invention relates to methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer, it also relates to the treatment of inflammatory diseases.

  • Gastrointestinal Drug
  • Infectious Disease
  • China
  • World
  • Product Initiative

Salix obtained the US and Canadian marketing rights in 2012 to Alfa Wassermann' s extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn' s disease.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Company
  • Salix Pharmaceuticals, Ltd.
  • Clinical Trial profile. 35 Trial Title
  • Clinical Trial Profile Snapshots

Gastrointestinal Disorders, Regurgitation Completed Phase IV Interventional baclofen University Hospitals Leuven Katholieke Universiteit Leuven ## Sep 2011 ## Sep 2013 ## ## ## GABAB Receptor (GABABR) Agonist Gamma-Aminobutyric Acid (GABA) B Receptor (GABBR) Official Title Clinical Trial pro

  • Cardiology
  • Gastrointestinal Drug
  • Health Services
  • Hospital
  • AstraZeneca PLC
  • Nov 18, 2014: Genetic Analysis pens first pharma collaboration with US Rebiotix

GA will present new data on the power of the GA-mapTM IBS/ IBD test in discerning healthy people from peopled suffering from various gastrointestinal disorders.

  • Gastrointestinal Drug
  • Europe
  • Norway
  • United States
  • GlobalData's company
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY CAMURUS AB, H2 2017

It also offers uPA and inhibitors for the treatment of gastrointestinal, solid tumor cancers, pancreatic and other gastrointestinal cancers.

  • Chemotherapy
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Helsinn Group
  • ITRIGLUMIDE PRODUCT DESCRIPTION
  • ROTTAPHARM SPA - DORMANT DEVELOPMENTAL PROJECTS,2015

Through their action in CCK## receptors in the gastrointestinal system, it increases gastric emptying and intestinal motility as well as modulating intestinal sensitivity to distension.

  • Gastrointestinal Drug
  • United States
  • World
  • Product Initiative
  • Rottapharm S.p.A.
  • ASP-1017
  • ASP-7663

These serotonin receptors exist in smooth muscle and neurons in gastrointestinal tract.

  • Gastrointestinal Drug
  • Prostate Cancer
  • Research And Development
  • United States
  • Astellas Pharma Inc.
  • KEY FACTS
  • Product Description

They are gastrointestinal antiinflammatory agents.

  • Gastrointestinal Drug
  • Research And Development
  • World
  • Product Initiative
  • Ferring International Center S.A.